CLBCore Laboratories Inc.

$10.17-15% 1Y

CLB as reported

Core Laboratories Inc. reported $519M of revenue over the trailing twelve months, +0.35% on the year before. 11 reported series are charted on this page, each one as filed.

$519M

Revenue, trailing twelve months · to Q2 2026 · +0.35% against the twelve months before

Net income
$24M

Net income · −18% year on year · trailing twelve months to Q2 2026

Free cash flow
$15M

Free cash flow · −64% year on year · trailing twelve months to Q2 2026

Operating margin
9.0%

Operating margin · trailing twelve months to Q2 2026

Details›
Every series Ryufin has for CLB, trailing twelve months
SeriesLatestYear on yearAs of
Revenue$519M+0.35%Q2 2026
Net income$24M−18%Q2 2026
EPS$0.52−17%Q2 2026
Gross margin19%n/aQ2 2026
Operating margin9.0%n/aQ2 2026
Net margin4.6%n/aQ2 2026
ROE11%n/aQ2 2026
ROA4.9%n/aQ2 2026
ROIC12%n/aQ2 2026
Free cash flow$15M−64%Q2 2026
P/E19.6n/atoday

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.

Revenue and profitCore Laboratories Inc. (CLB)
RevenueNet incomeTrailing twelve months
Powered byryufin.com